Dapsone is part of the multi-drug therapy used in the treatment of leprosy. It can cause life-threateninghypersensitivity syndromes resulting in significant morbidity and mortality, especially amongsusceptible individuals such as those who are carriers of HLA-B*13:01 allele. Avoidance of dapsonein these susceptible individuals reduces the risk of dapsone-related adverse events. Herein, we reportfour indigenous patients with leprosy who developed dapsone hypersensitivity syndrome.